Xeris Biopharma (XERS) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$335.4M

Revenue (quarter)

$92.1M

Revenue growth (year over year)

+28.74%

Gross profit (trailing twelve months)

$290.4M

Gross margin

86.58%

Net income (trailing twelve months)

−$17.2M

Net income (quarter)

−$31.1M

Net income growth (year over year)

−1513.12%

Net margin

−5.12%

Return on equity

—

EPS (trailing twelve months)

−$0.10

Book value per share

−$0.06

P/E (trailing twelve months)

—

Price to book

—

Debt to assets

102.36%

Payout ratio

—

Dividend yield

—

Company profile

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

• Is Xeris Biopharma (XERS) profitable?

  No. Xeris Biopharma reported a net loss of $17.2M over the trailing twelve months.

• How much revenue does Xeris Biopharma (XERS) make?

  Xeris Biopharma generated $335.4M in revenue over the trailing twelve months, up 28.74% year over year.

• How do I buy stock in Xeris Biopharma (XERS)?

  XERS trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.